Functions and Underlying Mechanisms of MiR-650 in Human Cancers

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2022 Mar 25

PMID 35331235

Authors

Yuanshuai Su

Qiuxian Zheng

Lingxiao Zhu

Xinyu Gu

Juan Lu

Lanjuan Li

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are one type of noncoding RNAs that interfere with mRNA translation to downregulate gene expression, which results in posttranscriptional gene silencing. Over the past two decades, miRNAs have been widely reported to impact the progression of malignant tumours by interfering with cancer initiation and progression; therefore, miRNAs represent potential new diagnostic and therapeutic tools. miR-650 is a newly identified miR, and increasing studies have demonstrated that miR-650 plays critical roles in cancer progression, such as mediating the Wnt signalling pathway/AXIN1 (axis inhibition protein 1) axis in hepatocellular carcinoma. Nevertheless, associations between the expression patterns and molecular mechanisms of miR-650 in cancer have not been comprehensively described. In this article, we review the existing evidence regarding the mechanisms by which miR-650 expression is altered and their relation to cancer. Moreover, the promising clinical application of miR-650 for diagnosis and treatment is highlighted.

Citing Articles

Dysregulated MicroRNAs in Chronic Lymphocytic Leukemia.

Mesaros O, Veres S, Onciul M, Matei E, Jimbu L, Neaga A Cureus. 2024; 16(9):e68770.

PMID: 39376808 PMC: 11456419. DOI: 10.7759/cureus.68770.

MicroRNA-650 promotes melanoma metastasis via targeting inhibitor of growth family member 4.

Chen C, Liu J, Ma Y, Wang Y, Cai L Heliyon. 2024; 10(16):e36199.

PMID: 39253208 PMC: 11382039. DOI: 10.1016/j.heliyon.2024.e36199.

Restoration of miR-650 leads to down-regulation of KISS1, a possible route involved in overcoming 5-FU resistance and induction of apoptosis in CRC cells in-vitro.

Valizadeh M, Babaei E, Sharifi R, Yazdanbod A Mol Biol Rep. 2023; 50(8):6591-6599.

PMID: 37341919 DOI: 10.1007/s11033-023-08451-z.

LncRNA DICER1-AS1 promotes colorectal cancer progression by activating the MAPK/ERK signaling pathway through sponging miR-650.

Li W, Ke C, Yang C, Li J, Chen Q, Xia Z Cancer Med. 2023; 12(7):8351-8366.

PMID: 36708020 PMC: 10134332. DOI: 10.1002/cam4.5550.

References

Zhou C, Cui F, Li J, Wang D, Wei Y, Wu Y . MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway. Oncotarget. 2017; 8(30):49534-49547. PMC: 5564786. DOI: 10.18632/oncotarget.17743. View

Yan R, He L, Li Z, Han X, Liang J, Si W . SCF(JFK) is a bona fide E3 ligase for ING4 and a potent promoter of the angiogenesis and metastasis of breast cancer. Genes Dev. 2015; 29(6):672-85. PMC: 4378198. DOI: 10.1101/gad.254292.114. View

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

Qu W, Jiang L, Hou G . Circ-AFF2/miR-650/CNP axis promotes proliferation, inflammatory response, migration, and invasion of rheumatoid arthritis synovial fibroblasts. J Orthop Surg Res. 2021; 16(1):165. PMC: 7923650. DOI: 10.1186/s13018-021-02306-8. View

Cui S, Gao Y, Zhang K, Chen J, Wang R, Chen L . The emerging role of inhibitor of growth 4 as a tumor suppressor in multiple human cancers. Cell Physiol Biochem. 2015; 36(2):409-22. DOI: 10.1159/000430108. View

Chao X, Wang S, Fulte S, Ma X, Ahamed F, Cui W . Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy. J Hepatol. 2021; 76(3):639-651. PMC: 8858859. DOI: 10.1016/j.jhep.2021.10.014. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Slattery M, Mullany L, Sakoda L, Samowitz W, Wolff R, Stevens J . The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression. J Cancer Res Clin Oncol. 2017; 144(2):269-283. PMC: 5794831. DOI: 10.1007/s00432-017-2548-6. View

Thrift A, El-Serag H . Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2019; 18(3):534-542. PMC: 8859863. DOI: 10.1016/j.cgh.2019.07.045. View

10.

Yuan C, Xu L, Du P, Pang J . miRNA-650 exerts anti-leukemia activity by inhibiting cell proliferation through Gfi1 targeting. Tumori. 2017; 104(5):369-374. DOI: 10.5301/tj.5000643. View

11.

Huang J, Cui S, Chen Y, Song H, Huang G, Feng B . MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One. 2013; 8(8):e72615. PMC: 3749147. DOI: 10.1371/journal.pone.0072615. View

12.

Farmer P, Frenk J, Knaul F, Shulman L, Alleyne G, Armstrong L . Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010; 376(9747):1186-93. DOI: 10.1016/S0140-6736(10)61152-X. View

13.

ODwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J . Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS One. 2012; 7(11):e48895. PMC: 3494711. DOI: 10.1371/journal.pone.0048895. View

14.

Gaine M, Sharpe D, Smith J, Colyer H, Hodges V, Lappin T . GATA2 regulates the erythropoietin receptor in t(12;21) ALL. Oncotarget. 2017; 8(39):66061-66074. PMC: 5630392. DOI: 10.18632/oncotarget.19792. View

15.

Chen J, Wu L, Sun Y, Luo C, Chen X, Wu L . Diagnostic value and clinical significance of circulating miR-650 and CA211 in detecting of gastric carcinoma. Oncol Lett. 2020; 20(5):254. PMC: 7509765. DOI: 10.3892/ol.2020.12117. View

16.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

17.

Schwartz H, Vingiano W, Perez C . Autonomy and the right to refuse treatment: patients' attitudes after involuntary medication. Hosp Community Psychiatry. 1988; 39(10):1049-54. DOI: 10.1176/ps.39.10.1049. View

18.

Bartel D, Chen C . Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004; 5(5):396-400. DOI: 10.1038/nrg1328. View

19.

Mason R, Au L, Ingles Garces A, Larkin J . Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother. 2019; 20(9):1135-1152. DOI: 10.1080/14656566.2019.1601700. View

20.

Zuo Z, Yu Y, Ding Y, Liu S, Martin A, Tseng G . Oncogenic Activity of miR-650 in Prostate Cancer Is Mediated by Suppression of CSR1 Expression. Am J Pathol. 2015; 185(7):1991-9. PMC: 4484220. DOI: 10.1016/j.ajpath.2015.03.015. View